Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: a bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey.

Fiche publication

Date publication

mars 2021

Journal

Clinics and research in hepatology and gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr LEPAGE Côme

Tous les auteurs :
Basile D, Gallois C, Puglisi F, Cohen R, Goere D, Aprile G, Lepage C, Laurent-Puig P, Maio MD, Lecomte T, Pernot S, Zaanan A, Taieb J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33785445

Résumé

Increasing evidence shows that circulating tumor DNA (ctDNA) is a valuable tool in providing molecular, prognostic, predictive and dynamic information in colorectal cancer (CRC) patients. This study aimed to make a picture of knowledge, practice, attitudes and expectations about ctDNA in CRC patients.